Sandra Oakes

Statistics

Publications

Citations

386

H-Index

Active since

2004

Affiliations

AstraZeneca (United Kingdom)(Current)

Sandra Oakes is an author at AstraZeneca (United Kingdom) specializing in cyclin-dependent kinases, cyclin-dependent kinase inhibitors, and drug discovery.

Publications per year

2004–2009

Publications

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew P. Thomas, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2009 · 122 citations

Medicine, Oncology, Pharmacology +17

Imidazo[1,2- a ]pyridines. Part 2 : SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors

Kate F. Byth, Janet D. Culshaw, Stephen Green et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 113 citations · Full text

Pharmacy, Medicinal Chemistry, Drug Design +13

Imidazo[1,2- b ]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors

Kate F. Byth, Nicola J. Cooper, Janet D. Culshaw et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 73 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

The cellular phenotype of AZ703, a novel selective imidazo[1,2-<i>a</i>]pyridine cyclin-dependent kinase inhibitor

Kate F. Byth, Catherine Geh, Cheryl Forder et al. · Molecular Cancer Therapeutics · 2006 · 48 citations · Full text

Medicine, Oncology, Pharmacology +15

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors

Malcolm Anderson, David Andrews, Andy Barker et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 30 citations · Full text

Pharmacy, Chemical Biology, Medicinal Chemistry +10

1–5 of 5